Search Within

Andrea Primiani Moy

Formats
  1. Journal Article (20)
  2. Meeting Abstract (6)
  3. Research Letter (4)
  4. Review (2)
  5. Correspondence (1)
  6. Miscellaneous (1)
Groups
  1. Department of Pathology and Laboratory Medicine (34)
  2. Melanoma Disease Management Team (34)
  3. Department of Medicine (22)
  4. Dermatology Service (21)
  5. Dermatology (19)
  6. Division of Subspecialty Medicine (19)

More Groups

People
  1. Mario Lacouture (13)
  2. Melissa Pulitzer (10)
  3. Klaus Busam (8)
  4. Alina Markova (7)
  5. Lukas Kraehenbuehl (6)
  6. Stephanie Gu (6)

More People

Years
  1. 2025 (5)
  2. 2024 (12)
  3. 2023 (5)
  4. 2022 (7)
  5. 2021 (3)
  6. 2020 (2)
Publications
  1. Journal of the American Academy of Dermatology (6)
  2. American Journal of Surgical Pathology (2)
  3. Clinical Cancer Research (2)
  4. Journal for ImmunoTherapy of Cancer (2)
  5. Journal of Allergy and Clinical Immunology (2)
  6. Journal of the American College of Surgeons (2)

More Publications

Publishers
  1. Mosby Elsevier (8)
  2. Elsevier Science, Inc. (4)
  3. Lippincott Williams & Wilkins (4)
  4. American Association for Cancer Research (2)
  5. Biomed Central Ltd (2)
  6. Elsevier Inc. (2)

More Publishers

Results (34)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Malignant CRTC1::TRIM11 cutaneous tumor with lethal outcome: Histopathologic and molecular findings
    Journal Article

    Beatson, M. E.; Smithy, J. W.; Domenico, D.; Gundem, G.; Papaemmanouil, E.; Moy, A.; Chen, J. M.; Pulitzer, M. P.; Ariyan, C.; Busam, K. J.
    Journal of Cutaneous Pathology (2025)

    Fulltext@MSK | Save
  • CCR8 immunohistochemistry highlights CCR8 as a diagnostic and therapeutic biomarker in cutaneous T-cell lymphoma
    Research Letter

    Geller, S.; Liao, V.; Moy, A.; Hollmann, T. J.; Pulitzer, M.
    Journal of Investigative Dermatology (2025)

    Fulltext@MSK | Save
  • Quantitatively defined stromal B cell aggregates are associated with response to checkpoint inhibitors in unresectable melanoma
    Journal Article

    Smithy, J. W.; Peng, X.; Ehrich, F. D.; Moy, A. P.; Yosofvand, M.; Maher, C.; Aleynick, N.; Vanguri, R.; Zhuang, M.; Lee, J.; more...
    Cell Reports (2025)

    Fulltext@MSK | Save
  • Declining clinical utility of tools for predicting sentinel lymph node biopsy status: A single institution experience from 2000 to 2021
    Journal Article

    Drebin, H. M.; Kurtansky, N. R.; Hosein, S.; Nadelmann, E.; Moy, A. P.; Ariyan, C. E.; Bello, D. M.; Brady, M. S.; Coit, D. G.; Marchetti, M. A.; more...
    Annals of Surgical Oncology (2025)

    Fulltext@MSK | Save
  • Mucocutaneous adverse events in patients with cancer treated with the highly selective RET kinase inhibitor selpercatinib (LOXO-292)
    Journal Article

    Reingold, R. E.; Parisi, R.; Harada, G.; Moy, A. P.; Dranitsaris, G.; Francis, J. H.; Canestraro, J.; Lester, J. A.; Kaplanis, L. A.; Liu, D.; more...
    JTO Clinical and Research Reports (2025)

    Fulltext@MSK | Save
  • Phenotype/immunologic profiling in ircAEs-response
    Correspondence

    Goleva, E.; Lacouture, M. E.; Moy, A. P.; Kern, J. A.; Leung, D. Y. M.
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma
    Journal Article

    Kudelka, M. R.; Richards, A. L.; Friedlander, P.; Wolchok, J. D.; Moy, A. P.; Shoushtari, A. N.
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Checkpoint inhibitor-related skin reactions in cancer patients are characterized by unique rash specific immune responses
    Meeting Abstract

    Goleva, E.; Lacouture, M.; Lyubchenko, T.; Gu, S.; Xiao, O.; Kraehenbuehl, L.; Berdyshev, E.; Ketosugbo, K.; Moy, A.; Rotemberg, V.; more...
    Journal of Allergy and Clinical Immunology (2024)

    Fulltext@MSK | Save
  • Superficial Wnt-activated melanocytic nevi/melanocytomas with a junctional component: A case series
    Journal Article

    Ng, S.; Hall, K. C.; Busam, K. J.; Lezcano, C.; Moy, A. P.; Pulitzer, M.; Sriharan, A.; Yan, S.; Linos, K.
    American Journal of Dermatopathology (2024)

    Fulltext@MSK | Save
  • Dupilumab for the treatment of dermatologic adverse events associated with MEK and EGFR inhibitors
    Meeting Abstract

    Zhang, Z.; Gu, S.; Dusza, S.; Moy, A.; Dunkel, I.; Drilon, A.; Diamond, E.; Lacouture, M.; Markova, A.
    Journal of the American Academy of Dermatology (2024)

    Fulltext@MSK | Save